March 1 press release is interesting/encouraging.....
Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced increased revenues during its first fiscal quarter 2016 of 143% compared to the same period in 2015, predominately due to further increased sales of its cell lines and MSC-Gro™ Brand of cell culture media products.
VODG remains a pretty attractive investment at current price levels, in my opinion. If/when the company fully updates its SEC filings, that should significantly reduce some of the additional/unnecessary risk that is currently present in the stock.
The stock has a history of pretty intense/unexpected price movements. It looks like there are a number of interesting announcements/developments that could be working their way forward, so it wouldn't be surprising at all to see some type of explosive high-volume spike or sustained move into a higher trading range in calendar 2016.
The March 1 press release is an encouraging sign that VODG's revenues may be regaining some consistency/momentum.......
First 6 months of 2015: $39K Second 6 months of 2015: $60K First quarter of 2016: $39K